NeuroBo Pharma Acquires ANA Therapeutics - Quick Facts

(RTTNews) - NeuroBo Pharmaceuticals Inc. (NRBO) said it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19.

NeuroBo said that ANA-001 is advancing through the 505(b)(2) clinical pathway, which allows the company to leverage earlier data on niclosamide and streamlines and accelerates the timelines to bring the potentially life-saving therapy to patients suffering with COVID-19.

As a result, the development timeline supports a number of value-creating milestones over the coming 12 to 18 months, including the data readout of the Phase 2 portion of the trial, expected in the third quarter of 2021.